• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

News at a glance: A win for obesity drugs, NIH unionization roadblocks, and Mexican fireflies under threat
CONSERVATION Researchers raise alarm over threat to Mexican fireflies Scientists from the International Union for Conservation of Nature (IUCN) last week delivered a letter to the Mexican government requesting it regulate tourism centered on the threatened firefly species Photinus palaciosi . Endemic to Mexico’s Tlaxcala forests, P. palaciosi is one of the few species that glow in synchrony, offering an annual spectacle that attracts thousands of visitors during summer mating season. The letter describes how littering, artificial light, and noise interfere with the insects’ courtship and eg...
Source: ScienceNOW - August 10, 2023 Category: Science Source Type: news

News at a glance: A win for obesity drugs, a new infectious disease institute head, and Mexican fireflies under threat
CONSERVATION Researchers raise alarm over threat to Mexican fireflies Scientists from the International Union for Conservation of Nature (IUCN) last week delivered a letter to the Mexican government requesting it regulate tourism centered on the threatened firefly species Photinus palaciosi . Endemic to Mexico’s Tlaxcala forests, P. palaciosi is one of the few species that glow in synchrony, offering an annual spectacle that attracts thousands of visitors during summer mating season. The letter describes how littering, artificial light, and noise interfere with the insects’ courtship and eg...
Source: Science of Aging Knowledge Environment - August 10, 2023 Category: Geriatrics Source Type: research

The U.S. Still Doesn ’ t Have Good COVID-19 Data. Here ’ s Why That ’ s a Problem
Check the COVID-19 Data Tracker from the U.S. Centers for Disease Control and Prevention (CDC), and you’ll get a rundown of the latest case numbers, hospitalizations, and deaths. Those categories might seem straightforward, but the data, say many experts, are telling us a lot less than we think they are. That’s because it’s getting increasingly difficult to parse who is hospitalized or dies from COVID-19, and who is hospitalized or dies from another reason but with COVID-19. Across the U.S., “COVID-19 hospitalizations” represent all kinds of patients: those who need hospital-level care for sev...
Source: TIME: Health - January 30, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

What Is or What Is Not a Risk Factor for Arterial Hypertension? Not Hamlet, but Medical Students Answer That Question
Int J Environ Res Public Health. 2022 Jul 5;19(13):8206. doi: 10.3390/ijerph19138206.ABSTRACTHypertension is a leading cause of cardiovascular disease and premature death worldwide. The most important method of preventing hypertension is social awareness of its causes. An important role in educating society about hypertension is played by medical personnel. The study involved 327 students of medicine representing all years of study. The study used a proprietary questionnaire containing test questions about knowledge of the causes of hypertension (classical and non-classical factors), as well as questionable and false risk ...
Source: Atherosclerosis - July 9, 2022 Category: Cardiology Authors: Tomasz Sobierajski Stanis ław Surma Monika Roma ńczyk Krzysztof Łabuzek Krzysztof J Filipiak Suzanne Oparil Source Type: research

IJERPH, Vol. 19, Pages 8206: What Is or What Is Not a Risk Factor for Arterial Hypertension? Not Hamlet, but Medical Students Answer That Question
ne Oparil Hypertension is a leading cause of cardiovascular disease and premature death worldwide. The most important method of preventing hypertension is social awareness of its causes. An important role in educating society about hypertension is played by medical personnel. The study involved 327 students of medicine representing all years of study. The study used a proprietary questionnaire containing test questions about knowledge of the causes of hypertension (classical and non-classical factors), as well as questionable and false risk factors for the disease. The students’ knowledge of the complicat...
Source: International Journal of Environmental Research and Public Health - July 5, 2022 Category: Environmental Health Authors: Tomasz Sobierajski Stanis ław Surma Monika Roma ńczyk Krzysztof Łabuzek Krzysztof J. Filipiak Suzanne Oparil Tags: Article Source Type: research

New Janssen Initiative Aims to Advance Equitable Care and Address Hidden Threat of Amputation Related to Peripheral Artery Disease (PAD)
TITUSVILLE, N.J., March 31, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the launch of Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now, a multi-year initiative aimed at creating urgency and action to address the hidden threat of peripheral artery disease (PAD)-related amputation, with an initial focus on reaching Black Americans, who are more than twice as likely to be impacted by PAD.1 Janssen has joined forces with leading professional associations, healthcare systems and community organizations to advance equitable care for individuals and communities placed at an...
Source: Johnson and Johnson - March 31, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Deferral of Care for Serious Non –COVID-19 Conditions
The harms of the coronavirus disease 2019 (COVID-19) pandemic have been innumerable, including illness, death and disability, unemployment and devastation of small businesses, hunger, educational losses, and amplification of racial and social inequities. In this issue of JAMA Internal Medicine, 2 articles shed light on another cost: deferral of care for serious non –COVID-19 conditions, such as myocardial infarction and stroke.
Source: JAMA Internal Medicine - October 26, 2020 Category: Internal Medicine Source Type: research